CADENCE PHARMACEUTICALS, INC COM STK
CADX
CADX was delisted on the 18th of March, 2014.
90 hedge funds and large institutions have $304M invested in CADENCE PHARMACEUTICALS, INC COM STK in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
15% more funds holding
Funds holding: 78 → 90 (+12)
10% less capital invested
Capital invested by funds: $337M → $304M (-$33.5M)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
37% less call options, than puts
Call options by funds: $67K | Put options by funds: $107K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
+$4.86M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.27M |
| 3 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
+$1.59M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.25M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$871K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.57M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.43M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.33M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.86M |
CADX Hedge Fund Activity: Q3 2013 in Review
90 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in CADENCE PHARMACEUTICALS, INC COM STK (CADX) for Q3 2013, worth a combined $304M — down 9.9% from $337M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CADX positions and 6 closed out — a net gain of 12 holders — while 27 added to existing stakes and 31 trimmed.
The largest buyer was CR Intrinsic Investors, opening a new position worth an estimated $4.86M. The largest seller was Invesco, exiting entirely with an estimated $4.57M sold.
- 90 institutional investors held CADENCE PHARMACEUTICALS, INC COM STK (CADX) as of Q3 2013, up from 78 in Q2 2013.
- Funds reported $304M of CADENCE PHARMACEUTICALS, INC COM STK stock for Q3 2013, down 9.9% quarter-over-quarter.
- 18 funds opened new CADENCE PHARMACEUTICALS, INC COM STK positions in Q3 2013 and 6 closed out, a net change of +12 holders.
- The largest CADENCE PHARMACEUTICALS, INC COM STK buyer in Q3 2013 was CR Intrinsic Investors, an estimated $4.86M added.
- The largest CADENCE PHARMACEUTICALS, INC COM STK seller in Q3 2013 was Invesco, an estimated $4.57M sold.
Based on aggregated 13F filings for Q3 2013.